DK16487A - Vacciner til oral indgift - Google Patents

Vacciner til oral indgift

Info

Publication number
DK16487A
DK16487A DK016487A DK16487A DK16487A DK 16487 A DK16487 A DK 16487A DK 016487 A DK016487 A DK 016487A DK 16487 A DK16487 A DK 16487A DK 16487 A DK16487 A DK 16487A
Authority
DK
Denmark
Prior art keywords
complex
immunogen
medicaments
well
cellular
Prior art date
Application number
DK016487A
Other languages
English (en)
Other versions
DK16487D0 (da
DK171846B1 (da
Inventor
Gregory John Russell-Jones
Henry James De Aizpurua
Peter Howe
Keith Norman Rand
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25642944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK16487(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Publication of DK16487D0 publication Critical patent/DK16487D0/da
Publication of DK16487A publication Critical patent/DK16487A/da
Application granted granted Critical
Publication of DK171846B1 publication Critical patent/DK171846B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DK016487A 1985-05-15 1987-01-14 Et kompleks, en fremgangsmåde til fremstilling af dette kompleks, en transformant vært, et rekombinant DNA-molekyle og et medikament for den specifikke stimulering af serum og sekretoriske antistoffer via mucøs tilstedeværelse af antigener DK171846B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPH056685 1985-05-15
AUPH056685 1985-05-15
AUPH310485 1985-10-25
AUPH310485 1985-10-25
PCT/AU1986/000135 WO1986006635A1 (en) 1985-05-15 1986-05-14 Oral vaccines
AU8600135 1986-05-14

Publications (3)

Publication Number Publication Date
DK16487D0 DK16487D0 (da) 1987-01-14
DK16487A true DK16487A (da) 1987-03-16
DK171846B1 DK171846B1 (da) 1997-06-30

Family

ID=25642944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK016487A DK171846B1 (da) 1985-05-15 1987-01-14 Et kompleks, en fremgangsmåde til fremstilling af dette kompleks, en transformant vært, et rekombinant DNA-molekyle og et medikament for den specifikke stimulering af serum og sekretoriske antistoffer via mucøs tilstedeværelse af antigener

Country Status (12)

Country Link
EP (1) EP0222835B2 (da)
JP (1) JP2761849B2 (da)
CN (1) CN86103835A (da)
CA (1) CA1340555C (da)
DE (1) DE3650082T3 (da)
DK (1) DK171846B1 (da)
ES (1) ES8900006A1 (da)
FI (1) FI870140L (da)
HK (1) HK29896A (da)
IL (1) IL78775A (da)
NZ (1) NZ216162A (da)
WO (1) WO1986006635A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8601940D0 (sv) * 1986-04-25 1986-04-25 Kabigen Ab Preparation of fused proteins, antibodies and processes therefor
US4822611A (en) * 1986-12-09 1989-04-18 Immunotec, Inc. Oral hyposensitization in the treatment of allergies
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5135918A (en) * 1988-03-21 1992-08-04 Broncorp Method for decreasing reaginic antibody levels
AU629237B2 (en) * 1988-08-30 1992-10-01 Applied Research Systems Ars Holding N.V. Recombinant fusion proteins for altering hormone secretion
ATE218797T1 (de) * 1988-09-06 2002-06-15 Univ Washington Orale-immunisierung durch verwendung von transgenen pflanzen
US6043057A (en) * 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2636842B1 (fr) * 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
EP0372928A3 (en) * 1988-12-07 1990-06-27 University Of Leicester Heat-labile toxin b subunit fusion proteins
WO1990007525A1 (en) * 1989-01-06 1990-07-12 The Regents Of The University Of California Keratoconjunctivitis cytotoxin and methods for its use and production
US6413523B1 (en) * 1989-06-02 2002-07-02 The United States Of America As Represented By The Secretary Of The Navy Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use
ATE99331T1 (de) * 1989-09-08 1994-01-15 Takeda Chemical Industries Ltd Fusionsproteine und herstellung davon.
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5378815A (en) * 1989-10-20 1995-01-03 National Research Council Canada Process for indirect targeted immunocytolysis
CA2050425A1 (en) * 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
US5843463A (en) * 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
DE69130955T2 (de) * 1990-12-21 1999-07-01 Antex Biologics, Inc., Gaithersburg, Md. Adhesin-oligosaccharid-impfstoffkonjugate für -i(haemophilus influenza)
PT501882E (pt) * 1991-03-01 2000-12-29 Merial Sas Processo de imunoneutralizacao anti-lhrm de animais domesticos machos nao castrados e peptido para esse fim
JP3296817B2 (ja) * 1991-04-02 2002-07-02 バイオテック・オーストラリア・ピーティーワイ・リミテッド 微粒子に適した経口配布系
GB9112553D0 (en) * 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
ZA934199B (en) * 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
DK0603992T4 (da) * 1992-12-22 2001-03-05 Univ Cincinnati Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
DK1323346T3 (da) * 1995-01-17 2006-10-30 Brigham & Womens Hospital Receptorspecifik transport af immunogener gennem epitelet
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
CA2227871A1 (en) * 1995-07-26 1997-02-13 Maxim Pharmaceuticals, Inc. Mucosal delivery of polynucleotides
DE19534579C2 (de) * 1995-09-18 2000-06-08 Max Planck Gesellschaft Nucleinsäure-Moleküle codierend Proteine, die die Adhäsion von Neisseria-Zellen an humane Zellen vermitteln
DE69736226T2 (de) 1996-04-19 2006-11-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
CA2252438C (en) 1996-04-19 2011-03-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
DE60017211T2 (de) 1999-02-17 2005-06-02 Pfizer Products Inc., Groton Fusionsproteine mit Trägern welche eine doppelte Immunantwort induzieren
FR2791895B1 (fr) * 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DE60043070D1 (de) 1999-10-22 2009-11-12 Genentech Inc Proteine-abgabe durch polare epithelzellen schichte
US6863896B1 (en) 1999-10-26 2005-03-08 Chiron Corporation Plant lectins as mucosal adjuvants
JP5072159B2 (ja) * 1999-10-26 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 粘膜アジュバントとしての植物レクチン
JP2001335510A (ja) * 2000-05-23 2001-12-04 Masanori Baba エイズワクチン
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
KR101319848B1 (ko) * 2004-07-20 2013-10-18 심포젠 에이/에스 재조합 폴리클로날 단백질 또는 폴리클로날 세포주의구조적 특성화 방법
AU2005296064A1 (en) 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
CN101365715B (zh) 2005-10-07 2013-03-27 P·安杰莱蒂分子生物学研究所 基质金属蛋白酶11疫苗
US7666991B2 (en) 2005-12-05 2010-02-23 Trinity Biosystems, Inc. Compositions for needleless delivery of antibodies
EP3011969A1 (en) 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
RU2536981C9 (ru) 2009-06-22 2015-05-10 ВАЙЕТ ЭлЭлСи Иммуногенные композиции антигенов staphylococcus aureus
CN101921726B (zh) * 2010-07-27 2012-08-22 浙江大学 一种口服免疫阻断鸡抑制素作用的转化子及其应用
CN102178699B (zh) * 2011-04-20 2013-03-20 威海康博尔生物药业有限公司 一种用于增强人体免疫力、促进生长发育的制剂
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2017066134A1 (en) 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2547224A1 (de) * 1974-11-01 1976-05-13 Sandoz Ag Organische verbindungen, ihre verwendung und herstellung
FR2306684A1 (fr) * 1975-04-11 1976-11-05 Crinex Lab Nouvelle composition a action immunostimulante
GB1553664A (en) * 1975-06-12 1979-09-26 Unilever Ltd Antigenic compositions
GR68404B (da) * 1979-06-01 1981-12-29 Univ California
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
CA1198385A (en) * 1980-03-17 1985-12-24 Leonard P. Guarente Optimal polypeptide production
EP0049945A3 (en) * 1980-09-15 1982-12-01 Bactex Incorporated Determining a hierarchy of piliated organisms and a vaccine prepared from such organisms
GB2094314A (en) * 1981-02-05 1982-09-15 Wellcome Found Recombinant DNA
WO1982003088A1 (en) * 1981-03-09 1982-09-16 Corp Cetus Vaccines
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
DE3382547D1 (de) * 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
AU582358B2 (en) * 1984-04-06 1989-03-23 Scripps Clinic And Research Foundation A peptide vaccine or diagnostic, and a polypeptide useful therefor
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
DE3586386T2 (de) * 1984-10-05 1993-01-14 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
NZ213759A (en) * 1984-10-19 1989-01-27 Genentech Inc Lhrh-ctp protein conjugates influencing prolactin fsh and lh release
US4556555A (en) * 1985-01-25 1985-12-03 North Carolina State University Process for the immunological neutering of animals

Also Published As

Publication number Publication date
JP2761849B2 (ja) 1998-06-04
FI870140A0 (fi) 1987-01-14
EP0222835A4 (en) 1988-02-01
FI870140A7 (fi) 1987-01-14
DE3650082T3 (de) 2000-12-21
CA1340555C (en) 1999-05-25
ES8900006A1 (es) 1988-10-16
IL78775A (en) 1992-06-21
AU5861286A (en) 1986-12-04
FI870140L (fi) 1987-01-14
CN86103835A (zh) 1987-04-08
DE3650082D1 (de) 1994-11-03
EP0222835B2 (en) 2000-04-19
NZ216162A (en) 1989-04-26
EP0222835A1 (en) 1987-05-27
HK29896A (en) 1996-02-23
DK16487D0 (da) 1987-01-14
EP0222835B1 (en) 1994-09-28
DE3650082T2 (de) 1995-05-04
AU594059B2 (en) 1990-03-01
WO1986006635A1 (en) 1986-11-20
ES554969A0 (es) 1988-10-16
JPH07213290A (ja) 1995-08-15
DK171846B1 (da) 1997-06-30
IL78775A0 (en) 1986-08-31

Similar Documents

Publication Publication Date Title
DK16487A (da) Vacciner til oral indgift
SE7602317L (sv) 1,4-dihydropyridinkarbonsyraalkylestrar till anvendning som lekemedel och sett att framstella desamma
IT7905216A0 (it) Soluzione di amminoacidi per pazienti affetti da carcinoma.
NO174877C (no) Fremgangsmåte for fremstilling av et legemiddel med antitumorvirkning
DK0548114T5 (da) Mometason-furoat-monohydrat, fremgangsmåde til fremtilling deraf og farmaceutiske præparater indeholdende dette
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
DK0526524T3 (da) Farmaceutiske præparater
IT8948599A0 (it) Procedimento per eliminare composti gassosi contaminanti, in particolare di droganti da gas vettori contenenti composti di alogenosilano
NL930015I2 (nl) Werkwijze ter bereiding van nonapepide-aminederivaten, en farmaceutische preparaten met ovulatie-opwekkende werking daaruit.
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
DK162445C (da) Pyranopyridiner, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende pyranopyridinerne
DK292587A (da) Kompleks, fremgangsmaade til fremstilling deraf og anvendelser af komplekset
NL7507268A (nl) Werkwijze ter bereiding van 1(alpha),24-dihydroxy-chole- calciferolen, alsmede derivaten en voorlopers daar- van , alsmede farmaceutische preparaten die deze ver- bindingen als actieve componenten bevatten.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
IT1140521B (it) Sistema medicinale da somministrare per via intradermica per dinitrato di isosorbite
DE69422712D1 (de) Tris-platin-komplexe
NO871599D0 (no) Sammensetning for stimulering av kondrocytter og osteoblaster (osseinhydroksyapatittforbindelse), fremgangsmaate for fremstilling derav og farmasoeytiske preparater inneholdende sammensetningen.
DK0521057T3 (da) Farmaceutiske midler indeholdende ipriflavon, fremgangsmåde til fremstilling deraf, og relativ terapeutisk anvendelse
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
BR9807332A (pt) Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
FI920428A0 (fi) Ett podofyllotoxinpreparat som innehaoller triglyserider.
KR900007816A (ko) 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도
DK52080A (da) Dehydropeptider fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
DK102787A (da) Isohexidnucleosider og farmaceutiske praeparater indeholdende disse

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment
B1 Patent granted (law 1993)
PBP Patent lapsed